Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Joseph E. Eid"'
Autor:
Anna Dmoszynska, Janusz Kloczko, Malgorzata Rokicka, Andrzej Hellmann, Ivan Spicka, Joseph E. Eid
Publikováno v:
Haematologica, Vol 92, Iss 4 (2007)
Background and Objectives Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative agent with unique erythropoietin receptor activity and a prolonged half-life, which has the potential for administration at extended dosing intervals.
Externí odkaz:
https://doaj.org/article/5906a608ed2e48b8a11d9c43ac4989b9
Autor:
Varnia Hungria, Roman Hájek, David S. Siegel, Thorsten Graef, Joseph E. Eid, Scott Vuocolo, Hilary A. Blacklock, Catherine D. Williams, Laura Rosiñol, Andrew Spencer, Kenneth C. Anderson, Junyuan Qi, Sagar Lonial, Thierry Facon, Hartmut Goldschmidt, Jennifer Houp, Meletios A. Dimopoulos, L. Sun, Antonio Palumbo
Publikováno v:
The Lancet Oncology. 14:1129-1140
Summary Background We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma. Methods In our randomised, double-blind, placebo-controlled, phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663cd55955b1420c133627f8a1c50565
https://doi.org/10.1016/s1470-2045(13)70398-x
https://doi.org/10.1016/s1470-2045(13)70398-x
Autor:
Arthur P. Staddon, Jean-Yves Blay, Yang Song, Thierry Alcindor, Lee D. Cranmer, Frank G. Haluska, Sant P. Chawla, Scot Ebbinghaus, George D. Demetri, Daniel A. Rushing, Nicolas Penel, Isabelle Ray-Coquard, Mohammed M. Milhem, John W. Loewy, Richard F. Riedel, Pierre F. Dodion, Ruey Min Lee, Emmanuelle Bompas, Peter Reichardt, B. Bui-Nguyen, Joseph E. Eid, Axel Le Cesne
Publikováno v:
Journal of Clinical Oncology. 31:2485-2492
Purpose Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of systemic chemotherapy used to treat metastatic sarcomas. This large randomized placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddbf4fec9d18f349dc459bbbf51bd3b3
https://doi.org/10.1200/jco.2012.45.5766
https://doi.org/10.1200/jco.2012.45.5766
Autor:
Lia Gore, Terri Warren, Cinara D. McCarthy, Joseph Aisner, Amita Patnaik, S. Gail Eckhardt, Robert S. Benjamin, Razelle Kurzrock, Stephen Leong, Joseph E. Eid, Gerard Greig, Kai Habben
Publikováno v:
Clinical Cancer Research. 16:2458-2465
Purpose: A phase I study was conducted to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of R1507—a fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor. Experimental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc4a9972d6870f7f3c49fb184b5ca15
https://doi.org/10.1158/1078-0432.ccr-09-3220
https://doi.org/10.1158/1078-0432.ccr-09-3220
Autor:
Ivan Spicka, Anna Dmoszynska, Joseph E. Eid, Janusz Kloczko, Malgorzata Rokicka, Andrzej Hellmann
Publikováno v:
Haematologica. 92:493-501
Background and Objectives Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative agent with unique erythropoietin receptor activity and a prolonged half-life, which has the potential for administration at extended dosing intervals.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b49bcb537debd5153e184a3a29dbae
https://doi.org/10.3324/haematol.10730
https://doi.org/10.3324/haematol.10730
Autor:
Allen S. Yang, Xing Sun, Alessandra Tosolini, Ivana Gojo, Mark Kirschbaum, Gregory M. Lubiniecki, Lisa Kujawski, Jean Pierre J. Issa, Christopher Bredeson, Stuart L. Goldberg, Peter W. Marks, Paul Frankel, Joseph E. Eid
Publikováno v:
British journal of haematology. 167(2)
Summary Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) may respond to treatment with epigenetic-modifying agents. Histone deacetylase inhibitors may synergize with hypomethylating agents. This phase 1 dose-escalation st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58df31c88ba8c70d4a2fd77191d47117
https://pubmed.ncbi.nlm.nih.gov/25040094
https://pubmed.ncbi.nlm.nih.gov/25040094
Autor:
Christine K. Gause, Simon Durrant, Meletios A. Dimopoulos, Kenneth C. Anderson, Arnon Nagler, Hartmut Goldschmidt, Thorsten Graef, Xavier Leleu, Fritz Offner, David S. Siegel, Scott Vuocolo, Sundar Jagannath, Jonathan L. Kaufman, Joseph E. Eid, Jennifer Houp
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 16:329-334.e1
Background The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::173d492d978dac27307898b1a6db898c
https://doi.org/10.1016/j.clml.2016.02.042
https://doi.org/10.1016/j.clml.2016.02.042
Autor:
John A. Glaspy, Paul Mainwaring, Vera Hirsh, Rodryg Ramlau, Joseph E. Eid, Christian Manegold
Publikováno v:
Trials
Trials, Vol 8, Iss 1, p 8 (2007)
Trials, Vol 8, Iss 1, p 8 (2007)
Background C.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d8ada8e4643cc1d88215105b13ce38
https://doi.org/10.1186/1745-6215-8-8
https://doi.org/10.1186/1745-6215-8-8
Autor:
Stephen Couban, Jiri Mayer, Juan Luis Steegmann, Joseph E. Eid, Anders Österborg, Andrzej Hellmann
Publikováno v:
British journal of haematology. 136(5)
Summary Anaemia is a common complication in the treatment of patients with aggressive non-Hodgkin lymphoma (NHL), but there are no published data on the effect of erythropoiesis-stimulating agents in such patients. This is the first open-label, phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65621549ffefe7c60f2f1e35bb00d8a1
https://pubmed.ncbi.nlm.nih.gov/17313376
https://pubmed.ncbi.nlm.nih.gov/17313376
Publikováno v:
American journal of hematology. 74(2)
Hydroxyurea has been extensively used in patients with sickle cell anemia and severe sickle cell-hemoglobin C (SC) disease to reduce the severity of their diseases. We report here our experience with an adult patient with severe SC disease who develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb6e3975d514763d69916ae7c122e7a2
https://pubmed.ncbi.nlm.nih.gov/14508799
https://pubmed.ncbi.nlm.nih.gov/14508799